Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella.

@article{Jones1991AntimicrobialAO,
  title={Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella.},
  author={R. Jones and M. Erwin and M. S. Barrett},
  journal={Diagnostic microbiology and infectious disease},
  year={1991},
  volume={14 6},
  pages={
          519-21
        }
}
Three new, orally administered cephalosporins (BK-218, cefdinir, RU29246) were tested against 13 representative strains of Legionella. Cefdinir was most active [50% minimum inhibitory concentration (MIC50), 1 micrograms/ml], a potency comparable to the reference drug cefixime and eightfold less active than erythromycin. BK-218 was the least active cephalosporin (MIC50, 8 micrograms/ml) or 100-fold less potent than rifampin. These investigational cephems appear poorly suited by activity assays… Expand
6 Citations
In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability.
TLDR
Cefdinir was equally effective against both standard and high inocula of S. aureus strains producing A, B, C, or D beta LAC types and MICs were also generated versus quality-control reference strains. Expand
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates
TLDR
RU29246 was the only cephalosporin consistently active against Acinetobacter, but all beta-lactam antibiotics had poor activity againstPseudomonas spp. Expand
Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin
  • D. Guay
  • Medicine
  • The Pediatric infectious disease journal
  • 2000
TLDR
The pharmacodynamic and pharmacokinetic characteristics of cefdinir as described in this paper, as well as the results of the clinical trials program, support the use of this agent in the treatment of a wide variety of pediatric infectious diseases. Expand
Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin.
  • D. Guay
  • Medicine
  • Clinical therapeutics
  • 2002
TLDR
Cefdinir is an alternative to other antimicrobial agents and can be dosed once or twice daily for the treatment of upper and lower respiratory tract infections and skin and skin-structure infections. Expand
Cefdinir: An Expanded-Spectrum Oral Cephalosporin
  • D. Guay
  • Medicine
  • The Annals of pharmacotherapy
  • 2000
TLDR
Cefdinir is a second-line alternative to first-line antimicrobial agents, with convenient once- or twice-daily dosing in the treatment of upper and lower respiratory tract infections and skin and skin-structure infections. Expand
Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.
TLDR
Cefixime is an effective treatment for mild to moderate LRTI and may have a role as the oral component of intravenous to oral switch therapy although further well designed studies are needed to confirm initial favourable results in this important emerging area of antibacterial therapy. Expand

References

SHOWING 1-10 OF 16 REFERENCES
In vitro investigation of BK-218, a new oral and parenteral cephalosporin
TLDR
BK-218 proved to be a good inhibitor for all five of the beta-lactamases that were investigated, although two enzymes hydrolyzed it to some extent. Expand
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin
TLDR
FK482 was less active than cefixime against Citrobacter, Enterobacter, Morganella, Serratia, and Providencia species, with MICs for many isolates of greater than 8 micrograms/ml. Expand
In vitro antibacterial activity of FK482, a new orally active cephalosporin.
FK482 is a new orally active cephem antibiotic which offers some advantages over the commercially available oral beta-lactam antibiotics. It displayed a broad spectrum of activity in vitro againstExpand
Inactivation of beta-lactam antibiotics by Legionella pneumophila
  • K. Fu, H. Neu
  • Medicine, Biology
  • Antimicrobial Agents and Chemotherapy
  • 1979
TLDR
Beta-lactam-inactivating activity has been found in all sero-groups of Legionella pneumophila and could be detected in intact cells and released by ethylenediaminetetraacetic acid treatment, indicating that it is located in the periplasmic space. Expand
Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs
TLDR
Ofloxacin was very active against intracellular L. pneumophila in these experiments and should be studied in the therapy of human Legionnaires disease. Expand
Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media.
TLDR
BAM1 agar seemed the better of the two charcoal-free media as it gave more consistent growth and the inhibitory effect of charcoal was most marked on josamycin and pristinamycin. Expand
Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents
The activity of serial concentrations of different antimicrobial agents on the multiplication of Legionella pneumophila within human monocyte-derived macrophages was studied. The results led to theExpand
Antimicrobial Susceptibility of Intracellular Legionella pneumophila
TLDR
Results of susceptibility testing of organisms grown intracellularly are compared with results for organisms grown by standard tube dilution methods. Expand
Uptake of ciprofloxacin by human neutrophils.
TLDR
Intracellular ciprofloxacin was biologically active and produced a significant reduction in viable counts of intracellular Staphylococcus, aureus in the presence of extracellular concentrations as low as 0.5 mg/l. Expand
Liquid medium for growth of Legionella pneumophila
TLDR
The medium described is a simple yeast extract broth capable of growing large number of Legionella neumophila, the causative organism of Legionnaires disease, which gave rapid cell growth and maintained the initial antigen production. Expand
...
1
2
...